echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Innovative drugs drive outsourcing industry, 2022 China's CRO industry penetration rate will increase to 40%

    Innovative drugs drive outsourcing industry, 2022 China's CRO industry penetration rate will increase to 40%

    • Last Update: 2020-05-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      Pharmaceutical Network Market Analysis: With the introduction of national policies to encourage the development of innovative drugs, enterprises in the research and development of innovative drugs to increase investment, more and more small-scale start-up biopharmaceutical companies set up, and the establishment of these pharmaceutical companies will rely more on CRO services, so the industry predicts that the future CRO demand and business penetration will rapidly increase
    It is understood that in the past, China's pharmaceutical enterprises more attention and generic drug development, the demand for CRO is weak, compared with the global CRO industry penetration rate, China's CRO industry penetration rate is low, but in recent years, with the development of China's innovative drugs, the demand for CRO and CRO business penetration gradually increased Data show that China's CRO industry penetration rate from 25.8% in 2013 to 32.4% in 2018, is expected to grow to 40.3% in 2022
    For the domestic, before the implementation of the band procurement policy in 2018, the rapid development of solid formulation consistency evaluation and innovative drugs led to a rapid increase in domestic DEMAND in the CRO industry After the introduction of the band procurement policy in 2018, generic drug prices have dropped significantly, profits have been greatly reduced, pharmaceutical companies have had to slash the consistency evaluation of the project, to innovative drugs Since 2019, the growth of domestic DEMAND for CRO services has been driven by the rapid growth of demand for innovative drug research and development services From consistency evaluation to innovative drug research and development, pharmaceutical companies demand increased technical capabilities for CRO enterprises, the industry said In this process of transformation, enterprises with higher service levels and better quality systems will benefit first
    In terms of market potential, the CRO market is expanding In the future, with the transfer of overseas production capacity to China and the continuous development of innovative drugs in China, research and development expenditure is increasing, the penetration rate of CRO in China is expected to continue to improve At the same time, analysts pointed out that according to the annual report disclosed by the major CRO companies in 2019, the industry invested a lot in research and development, talent is a large productivity of CRO enterprises
    From the talent point of view, CRO is a very high proportion of manpower costs of the industry, especially for master's degree and above the demand for highly educated personnel, is the CRO enterprises can not avoid the problem At present, the dividend of domestic engineers, labor costs are low, the trend of capacity transfer is obvious But in the long run, as domestic labor costs continue to increase, this is bound to become a constraint on CRO enterprises
    With the research and development of new drugs, production process development of increasing difficulty, the cost continues to increase The cost of research and development in pharmaceutical companies will continue to increase At the same time, patent cliff, medical insurance control fees and so on make large pharmaceutical companies operating pressure increased, control cost demand increased, large pharmaceutical companies through the divestiture of non-core business, more focus on key product research and development, CRO can help pharmaceutical companies to save costs, improve efficiency, the future enterprises will be increasing demand for CRO
    In addition, industry sources pointed out that due to the rapid growth of research and development spending by domestic pharmaceutical companies, as well as the improvement of the domestic policy environment and natural cost advantages, the global pharmaceutical outsourcing industry chain to China began to shift
    In recent years, for example, due to the rapid rise in the cost of new drug research and development and the pressure of health care control fees, more and more pharmaceutical companies through strategic divestiture to focus more of their business on the core areas of drug research and development Many of the world's big pharmaceutical companies are increasingly spun off and outsourced the development and production of small molecule drugs, focusing more on the development of macromolecule drugs This has been in the development of small molecule drug technology, production has accumulated a lot of technical advantages of domestic CDMO enterprises to bring development opportunities
    It is understood that the domestic CRO industry has been on track since 2016 and is in a period of rapid development In the future, with the research and development centers of multinational pharmaceutical companies to China," China's pharmaceutical research and development industry chain is becoming more and more mature, in the next few years, the domestic CRO market size will be further increased.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.